191 related articles for article (PubMed ID: 12973686)
1. Co-expression of trypsin and tumour-associated trypsin inhibitor (TATI) in colorectal adenocarcinomas.
Solakidi S; Tiniakos DG; Petraki K; Stathopoulos GP; Markaki I; Androulakis G; Sekeris CE
Histol Histopathol; 2003 Oct; 18(4):1181-8. PubMed ID: 12973686
[TBL] [Abstract][Full Text] [Related]
2. Tumour-associated trypsin inhibitor TATI is a prognostic marker in colorectal cancer.
Koskensalo S; Hagström J; Louhimo J; Stenman UH; Haglund C
Oncology; 2012; 82(4):234-41. PubMed ID: 22508321
[TBL] [Abstract][Full Text] [Related]
3. Tumor-associated trypsin inhibitor in normal and malignant renal tissue and in serum of renal-cell carcinoma patients.
Lukkonen A; Lintula S; von Boguslawski K; Carpén O; Ljungberg B; Landberg G; Stenman UH
Int J Cancer; 1999 Nov; 83(4):486-90. PubMed ID: 10508484
[TBL] [Abstract][Full Text] [Related]
4. High tissue expression of tumour-associated trypsin inhibitor (TATI) associates with a more favourable prognosis in gastric cancer.
Wiksten JP; Lundin J; Nordling S; Kokkola A; Stenman UH; Haglund C
Histopathology; 2005 Apr; 46(4):380-8. PubMed ID: 15810949
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of trypsinogen and tumor-associated trypsin inhibitor (TATI) in bladder cancer.
Hotakainen K; Bjartell A; Sankila A; Järvinen R; Paju A; Rintala E; Haglund C; Stenman UH
Int J Oncol; 2006 Jan; 28(1):95-101. PubMed ID: 16327984
[TBL] [Abstract][Full Text] [Related]
6. Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum.
Paju A; Vartiainen J; Haglund C; Itkonen O; von Boguslawski K; Leminen A; Wahlström T; Stenman UH
Clin Cancer Res; 2004 Jul; 10(14):4761-8. PubMed ID: 15269150
[TBL] [Abstract][Full Text] [Related]
7. Effects of radiation therapy on tissue and serum concentrations of tumour associated trypsin inhibitor and their prognostic significance in rectal cancer patients.
Gaber A; Stene C; Hotakainen K; Nodin B; Palmquist I; Bjartell A; Stenman UH; Jeppsson B; Johnson LB; Jirström K
Radiat Oncol; 2011 Aug; 6():100. PubMed ID: 21864386
[TBL] [Abstract][Full Text] [Related]
8. Real-time PCR quantification of human telomerase reverse transcriptase (hTERT) in colorectal cancer.
Saleh S; Lam AK; Ho YH
Pathology; 2008 Jan; 40(1):25-30. PubMed ID: 18038311
[TBL] [Abstract][Full Text] [Related]
9. Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242.
Pasanen P; Eskelinen M; Kulju A; Penttilä I; Janatuinen E; Alhava E
Scand J Clin Lab Invest; 1995 Apr; 55(2):119-24. PubMed ID: 7667604
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells.
Paju A; Hotakainen K; Cao Y; Laurila T; Gadaleanu V; Hemminki A; Stenman UH; Bjartell A
Eur Urol; 2007 Dec; 52(6):1670-9. PubMed ID: 17306443
[TBL] [Abstract][Full Text] [Related]
11. Increased serum levels of tumour-associated trypsin inhibitor independently predict a poor prognosis in colorectal cancer patients.
Gaber A; Nodin B; Hotakainen K; Nilsson E; Stenman UH; Bjartell A; Birgisson H; Jirström K
BMC Cancer; 2010 Sep; 10():498. PubMed ID: 20849596
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma.
Lee YC; Pan HW; Peng SY; Lai PL; Kuo WS; Ou YH; Hsu HC
Eur J Cancer; 2007 Mar; 43(4):736-44. PubMed ID: 17267202
[TBL] [Abstract][Full Text] [Related]
13. High expression of tumour-associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancer.
Gaber A; Johansson M; Stenman UH; Hotakainen K; Pontén F; Glimelius B; Bjartell A; Jirström K; Birgisson H
Br J Cancer; 2009 May; 100(10):1540-8. PubMed ID: 19384300
[TBL] [Abstract][Full Text] [Related]
14. Tumour-associated trypsin inhibitor, carcinoembryonic antigen and acute-phase reactant proteins CRP and alpha1-antitrypsin in patients with gastrointestinal malignancies.
Solakidi S; Dessypris A; Stathopoulos GP; Androulakis G; Sekeris CE
Clin Biochem; 2004 Jan; 37(1):56-60. PubMed ID: 14675563
[TBL] [Abstract][Full Text] [Related]
15. Tumour-associated trypsin inhibitor and tumour-associated trypsin.
Stenman UH
Scand J Clin Lab Invest Suppl; 1990; 201():93-101. PubMed ID: 2244188
[TBL] [Abstract][Full Text] [Related]
16. Human trypsinogen in colorectal cancer.
Williams SJ; Gotley DC; Antalis TM
Int J Cancer; 2001 Jul; 93(1):67-73. PubMed ID: 11391623
[TBL] [Abstract][Full Text] [Related]
17. Trypsinogen-1, -2 and tumour-associated trypsin-inhibitor in bile and biliary tract tissues from patients with biliary tract diseases and pancreatic carcinomas.
Hedström J; Haglund C; Leinonen J; Nordling S; Stenman UH
Scand J Clin Lab Invest; 2001 Apr; 61(2):111-8. PubMed ID: 11347977
[TBL] [Abstract][Full Text] [Related]
18. Nuclear factor-kappa B regulates cyclooxygenase-2 expression and cell proliferation in human colorectal carcinoma tissue.
Yu LL; Yu HG; Yu JP; Luo HS
Eksp Onkol; 2004 Mar; 26(1):40-7. PubMed ID: 15112579
[TBL] [Abstract][Full Text] [Related]
19. Telomerase activity and hTERT mRNA in development and progression of adenoma to colorectal cancer.
Kanamaru T; Tanaka K; Kotani J; Ueno K; Yamamoto M; Idei Y; Hisatomi H; Takeyama Y
Int J Mol Med; 2002 Aug; 10(2):205-10. PubMed ID: 12119560
[TBL] [Abstract][Full Text] [Related]
20. Association of ets-related transcriptional factor E1AF expression with tumour progression and overexpression of MMP-1 and matrilysin in human colorectal cancer.
Horiuchi S; Yamamoto H; Min Y; Adachi Y; Itoh F; Imai K
J Pathol; 2003 Aug; 200(5):568-76. PubMed ID: 12898592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
